Introduction
Takotsubo syndrome is an acute and usually reversible heart failure syndrome first described in 1990 which is increasingly recognised with access to urgent coronary angiography for patients with acute 'cardiac' chest pain. 1 Since the initial description, the clinical community has increasingly recognized that this syndrome is distinct from acute coronary syndrome (ACS), although the initial presentation has similar features to ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI). [2] [3] [4] [5] [6] [7] [8] [9] [10] Early access to diagnostic coronary angiography has helped identify this condition, and the number of case reports, series and registries reported has increased over the last 25 years, offering different insights into this syndrome.
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To date there have been no randomised trials to define the optimal management of patients with suspected Takotsubo syndrome, with respect to both diagnosis and treatment. The increasing variety of clinical contexts in which this syndrome has been described implies that multiple pathophysiological processes may converge to generate a similar clinical phenotype. As a result, clinical decisions are challenging, and many patients currently receive a 'default' ACS management strategy.
The published literature on Takotsubo syndrome and related stress-induced cardiac syndromes consists of case reports, case series, observational cohorts from screening discharge coding across healthcare networks, and data collected from national Takotsubo syndrome registries. These registries vary in size but are generally considered small by contemporary standards (<600 patients). This current published information is level of evidence C for conventional clinical guidelines. This document is a position statement and not a guideline; current evidence was reviewed by a group of experts with a specialist interest in Takotsubo syndrome who provided their opinion and consensus of the current best practice for the diagnosis and management of patients with Takotsubo syndrome.
Nomenclature
Various names have been used to describe the acute appearance now classically described as a 'Takotsubo cardiomyopathy' or 'Takotsubo syndrome', following the initial label given by Sato and colleagues in 1990 and 1991, which reflects the resemblance of the left ventricle at end-systole to the octopus pots of Japanese fisherman in the Hiroshima fish markets. 12 Many alternatives names have been used, including stress or stress-induced cardiomyopathy, 13 apical ballooning syndrome, 3 ampullary-shaped cardiomyopathy, 14, 15 and 'broken heart syndrome' in the context of bereavement. 16 The authors suggest "Takotsubo syndrome" as a unifying term for this clinical entity. 'Takotsubo' has now become engrained in both medical literature and teaching, and several Takotsubo registries have been established. [17] [18] [19] [20] [21] Since the diagnosis is currently based on a series of clinical observations (see below), there is consensus that it fulfils the definition of a clinical syndrome. The term 'cardiomyopathy' implies a primary disease of the cardiac muscle and in clinical cardiology is usually applied to a primary heart muscle disorder of genetic or unknown origin. Patients with Takotsubo syndrome do not appear to have a primary muscle disorder, and no common genetic basis has been identified. The full recovery of patients and the low rate of major adverse cardiac events at follow-up in reported series strongly suggest that Takotsubo syndrome is different from the primary cardiomyopathies.
Definition
Takotsubo syndrome and associated variants are a form of acute and usually reversible heart failure syndrome. It may be a form of acute catecholaminergic myocardial stunning, as there is no occlusive coronary artery disease to explain the pattern of temporary left ventricular dysfunction observed.
Patients with Takotsubo syndrome have typical features that must be identified to confirm the diagnosis. Several previous diagnostic criteria have been proposed, including those by the Mayo Clinic (modified in 2008), the Japanese Takotsubo Cardiomyopathy Group, the Gothenburg Group, and the Takotsubo Italian Network. 4, 20, [22] [23] [24] We have reviewed, adapted and amended these criteria to generate the new 2015 Heart Failure Association of the European Society of Cardiology (HFA) Takotsubo Syndrome Diagnostic Criteria (Box 1). Although this condition predominantly affects postmenopausal women (~90% of all cases reported, particularly in larger cohorts), men and younger women can have this condition. Therefore, these demographic features are not a mandatory part of the proposed diagnostic criteria. Takotsubo syndrome is reversible-a critical feature that helps to differentiate it from many other acute heart failure syndromes. Timelines of recovery vary depending on the severity of the acute episode. As a guide, left ventricular ejection fraction (LVEF) usually recovers by 12 weeks, but ECG changes and brain natriuretic peptide (BNP) levels may take 6-12 months to recover and, in some cases, can remain permanently abnormal e.g. if myocardial scarring occurs.
Distinguishing Takotsubo syndrome from acute infective myocarditis can be challenging if there is evidence of acute myocardial oedema and inflammation in a typical anatomical distribution, as is common during the acute episode of Takotsubo syndrome (Box 2). [25] [26] [27] This could be considered a form of acute catecholaminergic myocarditis, given the appearance on T2-STIR cardiac magnetic resonance (CMR) and rise in cardiac troponin. A careful history and other clinical features can normally differentiate these conditions (e.g. the stressful trigger, if present, in Takotsubo syndrome versus the viral prodromal illness with fever in acute infective myocarditis).
28
Another difference from the modified Mayo diagnostic criteria is the inclusion of phaeochromocytoma. In patients with this condition, and particularly those with an epinephrinesecreting phaeochromocytoma, acute Takotsubo syndrome may result from a catecholamine storm, in an analogous manner to a catecholamine storm after a sudden stressful experience. [29] [30] [31] [32] [33] [34] The pathophysiology and clinical phenotype are identical, and therefore the consensus of the authors was to include patients with phaeochromocytoma but to consider them as cases of secondary Takotsubo syndrome (Table 1) .
Clinical subtypes: primary and secondary Takotsubo syndrome
Takotsubo syndrome comes to the attention of medical personnel in a variety of clinical scenarios and contexts. Cases can be classified as either primary or secondary Takotsubo syndrome.
Primary Takotsubo syndrome
In primary Takotsubo syndrome, the acute cardiac symptoms are the primary reason for seeking care, usually from emergency medical services, acute cardiac services, or the primary care physician. Such patients may or may not have clearly identifiable stressful triggers (often emotional). Potential coexisting medical conditions may be the predisposing risk factors but are not the primary cause of the catecholamine rise. These cases can be considered primary Takotsubo syndrome, and their clinical management depends on the specific complications.
Secondary Takotsubo syndrome
A substantial proportion of cases occur in patients already hospitalised for another medical, surgical, anaesthetic, obstetric or psychiatric condition. In these patients, sudden activation of the sympathetic nervous system or a rise in catecholamines precipitates an acute Takotsubo syndrome as a complication of the primary condition or its treatment. We propose that such cases be diagnosed as secondary Takotsubo syndrome. Their management should focus not only on the Takotsubo syndrome and its cardiac complications but also on the condition that triggered the syndrome. Examples of medical conditions reported to trigger secondary Takotsubo syndrome are listed in Table 1 .
Anatomical variants
Primary and secondary Takotsubo syndromes encompass an array of anatomical variants ( Table 2 and Figure 1 ). [35] [36] [37] The initial report of Takotsubo syndrome described what is now considered the classical pattern: left ventricular RWMA with apical and circumferential mid-ventricular hypokinesia and basal hypercontractility. At end-systole, the left ventricle typically resembles the ' Takotsubo' with a narrow neck and globular lower portion, giving the appearance of virtual apical ballooning.
This typical variant with apical dysfunction is present in ~50-80% cases, depending on the series.
Two other variants are common: the inverted Takotsubo or basal variant, with circumferential basal hypokinesia and apical hypercontractility, also referred to as the 'nutmeg' or 'artichoke' heart, and the mid left ventricular (MLV) variant, with circumferential mid-ventricular hypokinesia and both basal and apical hypercontractility. [38] [39] [40] The end-systolic appearance of the MLV variant has been likened to a Greek vase or the ace of spades; however, the basal variant also can also resemble the ace of spades (Figure 1 ). In both of these variants, reversible LV dysfunction affects more than one coronary territory, usually in a circumferential pattern, in the absence of culprit coronary artery disease. Rarer variants include biventricular apical dysfunction, dysfunction sparing the apical tip (possibly a form of MLV Takotsubo), and isolated RV Takotsubo syndrome. 36, [41] [42] [43] The affected LV segments may recover at different rates, a possible explanation for the various anatomical variants observed. Intriguingly, Takotsubo syndrome may recur as a different anatomical variant in the same patient, suggesting that a person can be susceptible to more than one subtype.
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Epidemiology
Several series of Asian and Western (predominantly Caucasian) populations suggest that 1-2% of patients with suspected ACS are eventually diagnosed with Takotsubo syndrome. 7, 37 In those series, the incidence of Takotsubo syndrome was likely underestimated. The possibility of pre-hospital sudden cardiac death from Takotsubo syndrome was not considered, and with increasing awareness and more widespread access to early coronary angiography, Takotsubo syndrome is now recognised more frequently.
The largest reported cohorts are from the Nationwide Inpatient Sample (NIS-USA). However these reports were based on ICD-10 discharge coding, with no uniform system for ensuring correct diagnosis or estimating the number of cases missed. This registry represents ~20% of all US nonfederal community hospitals. The first NIS-USA study reported data on 6837 patients with Takotsubo syndrome from 2008. 46 The second NIS-USA study reported data from 24,701 patients from 2008-
2009; it appears to be a 24-month dataset, but may include patients in the first study. 47 These numbers imply that there are ~50,000-100,000 cases per annum in the USA, with similar estimated numbers in Europe.
In the first study, Takotsubo syndrome was diagnosed in 0.02% of all acute hospitalizations (6837/33,506,402 patients). 46 The majority (90%) were elderly postmenopausal women (66-80 years of age), a demographic repeated across many published cohorts. The risk factors included smoking, alcohol abuse, anxiety states, and hyperlipidaemia. The second study, and largest cohort to date, reported details of 24,701 patients with a discharge code for Takotsubo syndrome. The demographics were similar to those in the first study: 89% were women, the mean age was 66.9 ± 30.7 years, and most patients (59.6%) were ≥65 years old.
47
Gender differences
Takotsubo syndrome occurs predominantly in postmenopausal women. The German Takotsubo syndrome registry includes 324 patients; 91% are female (mean age 68 ± 12 years) and 9% are male (mean age 66 ± 12 years). The demographic and clinical characteristics were similar in men and women. 17 However, emotional stress or the absence of identifiable triggers was more common in women. Conversely, a physical stressful triggering event, shock, or resuscitation on presentation was more common in men, who also had higher levels of cardiac biomarkers (troponin). In the larger of the two NIS-USA cohorts, the mortality rate was higher in men (8.4% vs 3.6%, p < 0.0001), perhaps reflecting the higher frequency of underlying severe critical illness and secondary Takotsubo syndrome (36.6% in men vs 26.8% in women, p < 0.0001).
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Age
Elderly patients are considered to be at higher risk of Takotsubo syndrome and related major complications, and less than 10% of patients are below 50 years of age. 46, 48 In the Takotsubo Italian Network, Takotsubo syndrome patients older than 65 years have a greater prevalence of hypertension, cerebrovascular disease, a lower glomerular filtration rate, and a lower LVEF at discharge compared to younger patients. Older adults (≥75 years) have higher rates of in-hospital complications and inhospital mortality (6.3% vs 2.8% overall in-hospital mortality).
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Pathophysiology
The pathophysiology of Takotsubo syndrome is complex and reflects the integrated and systemic physiological responses to acute, severe stress and the cardiovascular responses to sudden surges in endogenous or exogenously administered catecholamines. The pathophysiology has been extensively reviewed elsewhere.
10, [49] [50] [51] [52] Catecholamines appear to have a central role in the pathophysiology of Takotsubo syndrome, as the trigger is often a sudden, unexpected stress; signs of sympathetic activation are present at presentation, and secondary medical triggers can also lead to extreme sympathetic activation. There are two initial elements of the physiology to consider. The first is the cognitive centres of the brain and hypothalamic-pituitary-adrenal (HPA) axis, and how much epinephrine and norepinephrine are released in response to a given stress (i.e., the 'gain' of the HPA axis). The second is the response of the cardiovascular system (including the myocardium, coronary arteries, and peripheral vasculature) and the sympathetic nervous system to the sudden sympathetic activation and surge in circulating catecholamines.
Serum catecholamine levels at presentation are significantly higher than resting levels in the same patient or in comparable patients with acute heart failure due to acute myocardial infarction (MI), suggesting the potential for excessive HPA gain and epinephrine release. 53 Iatrogenic Takotsubo syndrome has been reported after administration of sympathomimetic drugs (e.g. dobutamine in stress echocardiography). 54 Several hypotheses have been proposed to explain the unique cardiac appearance in Takotsubo syndrome and the cardiac response to severe stress. These hypotheses can be broadly divided into vascular and myocardial causes (Box 3) and may not be mutually exclusive, as the entire cardiovascular system is exposed to the same catecholamine storm. Many of these hypotheses are still being investigated, as there is no current proven pathophysiological mechanism to explain Takotsubo syndrome. There may be a synergistic combination of more than one factor, and mechanistic studies have yielded conflicting results.
Genetic susceptibility
The stressful trigger implies that the pathophysiology of Takotsubo syndrome has a strong environmental component. However, it is conceivable that some people have a genetic predisposition to stress-induced Takotsubo syndrome. Although the syndrome is not considered a primary genetic cardiomyopathy, a number of studies have explored the possibility of genetic risk factors. A genetic predisposition has been suggested based on the few familial Takotsubo syndrome cases described. [55] [56] [57] [58] Conflicting results have been published regarding the presence or absence of functional polymorphisms in relevant candidate genes, such as α1-, β1-and β2-adrenergic receptors, GRK5, and oestrogen receptors. These studies had relatively small numbers of subjects. Resolving these conflicts will require high-quality phenotyping, identification of candidate genes, and sharing of highnumber/high-quality data in a Takotsubo syndrome network.
Clinical presentation and diagnosis
The typical patient with primary Takotsubo syndrome is a postmenopausal women who has experienced severe, unexpected emotional or physical stress. 4 This may be unheralded or on the background of elevated levels of stress or anxiety, including in some cases a formal diagnosis of anxiety or panic disorder. 46, 59 However, most patients do not have prior history of stress-related psychological conditions. Nevertheless, it is important to remember that 10% of cases in the largest reported series (NIS-USA) were men or younger women, and 30-35% of cohort series report classical cases in patients with no identifiable stressful trigger. 46 Thus, gender, menopausal status, and stressful triggers are not mandatory features and are not included in our HFA diagnostic criteria.
Patients with Takotsubo syndrome typically present with acute chest pain of cardiac origin Once the diagnosis of Takotsubo syndrome is suspected in the catheterization laboratory, early cardiac imaging and assessment of cardiac biomarkers can help exclude MI and further stratify risk.
Given the spectrum of clinical and anatomical patterns, the presence or absence of stressful triggers, and the potential presence of coronary artery disease or prodromal viral illnesses, borderline cases exist (see Diagnostic Algorithm). In such cases, CMR imaging with late gadolinium enhancement (LGE) may be helpful. 35, 36 CMR is also complementary to echocardiography to detect complications and aid risk stratification and has better sensitivity for detecting LV apical thrombus.
Secondary Takotsubo syndrome in specific clinical settings
Takotsubo syndrome can complicate a wide variety of acute medical and surgical conditions, including elective non-cardiac procedures (see Secondary Takostubo syndrome section and Table 1 ).
Iatrogenic causes during catecholamine administration (e.g., dobutamine stress echocardiography)
have also been reported. Therefore, clinicians should be alert to Takotsubo syndrome in numerous clinical settings, including the acute medical unit, endocrinology ward, neurology ward, anaesthetic room, intensive care units (including neuro-intensive care unit), obstetric unit, and psychiatric ward.
Takotsubo syndrome can be fatal because of mechanisms discussed below (see Complications and acute prognosis section). Many of these complications can be readily detected post-mortem in a confirmed case of Takotsubo syndrome. More difficult is the case of sudden non-hospital cardiac death in a patients with a stressful precipitant and a structurally normal heart and coronary arteries.
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These cases may have medico-legal or criminal implications, for example where sudden death occurs during restraint in police custody or in the psychiatric department. A more precise set of histopathological criteria is needed to help in post-mortem evaluation and diagnosis of Takotsubo syndrome as a cause of stress-induced sudden death.
Diagnostic investigations Biomarkers
Cardiac troponin measured by conventional assays (not high sensitivity) is elevated in more than 90%
of patients with Takotsubo syndrome. However, the rise in serum troponin or creatinine kinase is disproportionately low relative to the extent of RWMA and cardiac dysfunction (i.e., widespread segmental akinesia/hypokinesia of >5 segments and frequently >9 segments in the 17-segment model). 48 During the acute phase of Takotsubo syndrome, serum cardiac natriuretic peptides [BNP or the Nterminal fragment of brain natriuretic peptide (NT-proBNP)] are almost always elevated, frequently to extremely high levels that correlate more closely with the degree of ventricular wall motion abnormality. [63] [64] [65] [66] The limited evidence to date suggests that BNP and NT-proBNP are more useful diagnostic biomarkers than troponin, and it is recommended that they be measured in all suspected cases if the assay is available. Since normal levels are extremely rare in Takotsubo syndrome, an elevated natriuretic peptide level is included in the new diagnostic criteria (Box 1). NT-proBNP is a valuable marker of myocardial deterioration and recovery. Low NT-proBNP at admission may reliably indicate a favourable prognosis and hence is included in our proposed risk stratification criteria (Box 4).
Other biomarkers have been reported in research studies but are not currently recommended in routine practice. Serum catecholamines (epinephrine, norepinephrine, dopamine), neuropeptide-Y, and serotonin are typically elevated in Takotsubo syndrome. 53 Catecholamine levels are two to three time higher in patients with Takotsubo syndrome than in those with acute MI (Killip class III) at admission. This finding was reinforced by another study, although not all patients presented with elevated serum catecholamines. 5, 67 In a recent study, the profile of circulating microRNAs (small noncoding RNA sequences) differed in Takotsubo syndrome and STEMI patients, 68 supporting a different pathophysiology and the potential for developing future diagnostic biomarkers.
Electrocardiography
ECG abnormalities are present in more than 95% of Takotsubo syndrome patients during the acute phase. 7, 48, [69] [70] [71] Daily ECGs are helpful, as a typical evolution has now been defined, and the potential for worsening of QT interval is important in risk stratification and may help distinguish Takotsubo syndrome from STEMI. 72 However ECG criteria alone are not sufficient to differentiate Takotsubo syndrome from STEMI. 73 The ECG abnormalities during the acute phase (<12 hours) are ST-segment elevation, STsegment depression, new left bundle branch block and sometimes Q-waves, with deep and widespread T-wave inversion and significant QT prolongation developing 24-48 hours after the onset of symptoms or precipitating stressful trigger (when present). 70 If presentation is delayed, T-wave inversion and QTc prolongation without ST segment elevation might be observed. The QTc prolongation is often pronounced (>500 ms), predisposing to torsades de pointes and ventricular fibrillation. 17, 70 Significant QTc prolongation is seldom seen in STEMI caused by coronary occlusion and may help to differentiate the two conditions retrospectively; however, it should not be used for prospective diagnosis. A minority of Takotsubo syndrome patients may present with a normal ECG but this is atypical.
Coronary angiography and left ventriculography
Most Takotsubo syndrome patients should have urgent coronary angiography to exclude STEMI or NSTEMI because they present with cardiac chest pain and have ST elevation or other changes that could be interpreted as an ACS. In Takotsubo syndrome, the epicardial coronary arteries are typically normal and unobstructed; however, given the predilection for older patients, bystander coronary artery disease can be present. If so, it is important to consider whether the coronary artery disease is sufficient to cause the degree or pattern of LV dysfunction. Several studies reviewing cohorts of Takotsubo syndrome patients report bystander coronary artery disease in up to 10% of cases. 74, 75 Although not causative, bystander coronary artery disease is a risk factor for more severe heart failure during the acute episode (Box 4). Intravascular ultrasound studies have demonstrated that plaque rupture or intracoronary thrombosis is not present in Takotsubo syndrome. 76 Once causative coronary occlusion, including acute plaque rupture, thrombus formation, and coronary dissection, has been excluded, ventriculography should be performed unless there is a contraindication, since ventriculography will frequently be diagnostic for Takotsubo syndrome. This is important as the wall motion abnormalities may recover in hours and may be missed if imaging is delayed. The typical pattern of wall motion abnormality is the apical and mid-wall hypokinesis that earned this condition its original 'Takotsubo' label. However, other anatomical variants may occur (see Anatomical Variants, Figure 1 , and Table 2 ).
Echocardiography
Transthoracic echocardiography with colour and tissue Doppler should be the first non-invasive imaging technique to verify a suspected diagnosis of Takotsubo syndrome. Transthoracic echocardiography can assess LV morphology and function, identify anatomic variants, detect potential complications (e.g. LVOTO, mitral regurgitation, RV involvement, thrombus formation, and cardiac rupture) and monitor recovery. [77] [78] [79] Key echocardiographic features during the acute phase consist of a large area of dysfunctional myocardium extending beyond the territory of a single coronary artery and usually characterised by symmetrical regional abnormalities involving the midventricular segments of the anterior, inferior, and lateral walls (a circumferential pattern). 77 Among 227 patients enrolled in the Takotsubo Italian Network, low LVEF, elevated E/e´ ratio, reversible moderate-to-severe mitral regurgitation, and age ≥75 years correlated independently with major adverse events (acute heart failure, cardiogenic shock, and in-hospital death).
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Cardiac magnetic resonance CMR provides 3D anatomical information that can distinguish Takotsubo syndrome from other cardiac diseases and can help to elucidate its cause and pathophysiology. 35 It can accurately assess both LV and right ventricular (RV) regional function and demonstrate the typical patterns of RWMA ( Figure 1 and Table 2 ). Takotsubo syndrome involves the RV in up to one third of patients, and CMR often provides more complete views of the RV than echocardiography. 35 CMR is superior to echocardiography in detecting apical LV thrombi, and patients with large areas of apical akinesia may benefit from CMR if echocardiography is unclear. 81 During the acute phase of Takotsubo syndrome, T2-weighted CMR shows oedema of the LV myocardium as high signal intensity with a diffuse or transmural distribution in a distribution consistent with the wall motion abnormality. These features help distinguish between Takotsubo syndrome from myocarditis and acute MI. [25] [26] [27] [28] 82 Typically, LGE is usually absent in Takotsubo syndrome and its absence is an important distinguishing feature from MI. 35 It is controversial, however, whether minor LGE may be present in some patients with Takotsubo syndrome during the acute phase but absent at follow-up CMR. The frequency of LGE depends on the threshold of signal intensity used to define its presence. 83, 84 Atypical cases with small areas of persistent apical transmural LGE have been reported. 
Coronary computed tomography angiography (CCTA)
In diagnosing Takotsubo syndrome, it is essential to exclude coronary occlusion and significant coronary stenosis. This evaluation is usually done invasively, as the patient typically presents with a clinical picture closely resembling that of acute MI. However, for a delayed presentation (>48 hours after chest pain starts and the patient is pain free at the time of presentation) or for retrospective evaluation of a patient with the typical history of Takotsubo syndrome weeks or months previously, coronary stenoses can also be excluded by CCTA (Box 4). Acquiring information throughout the cardiac cycle (spiral or helical acquisition mode) during the acute phase can also demonstrate the typical pattern of systolic dysfunction but at the price of a higher radiation exposure. 85 Currently there is no evidence for delaying invasive coronary angiography in patients with ongoing acute chest pain and acute ECG changes. The ESC guidelines for STEMI or ACS should be followed until culprit coronary artery disease has been excluded.
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Radionuclide imaging
The role of radionuclide imaging in the diagnosis and management of Takotsubo syndrome is undetermined. When CMR is unavailable, myocardial perfusion scintigraphy may help exclude infarction in uncertain cases, and there are reports of normal or mildly reduced perfusion in the dysfunctional segments, but out of keeping with the scale of contractile dysfunction.
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Iodine-123 meta-iodo-benzyl-guanidine (mIBG) has been used to image myocardial sympathetic nerve terminal activity and to detect adrenal or ectopic phaeochromocytoma, which may be clinically relevant in these patients, although its precise role remains to be determined. During the acute phase, there is reduced mIBG in the dysfunctional myocardial segments, consistent with a regional disturbance of sympathetic neuronal activity. 87, 89 The abnormalities can persist for several months, and mIBG scintigraphy may have a role in cases without a diagnosis or when the presentation is remote from an acute episode (Box 4). Ideally, mIBG imaging should be combined with myocardial perfusion scintigraphy to exclude infarction; it is unknown whether persisting innervation abnormalities or increased mIBG washout, reflecting increased sympathetic tone, provides prognostic information.
Cardiac positron emission tomography using 18 F-2-fluoro-deoxy-glucose has shown abnormal glucose metabolism in the context of normal myocardial perfusion in patients with Takotsubo syndrome; however, it currently has been used only in a research context.
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Complications and acute prognosis
Takotsubo syndrome has generally regarded a relatively benign disease with rapid recovery of LV function. However, growing evidence suggests it is a more serious acute cardiac disorder with a variety of complications in ~52% of patients (Table 3) .
80, 91, 92
Acute heart failure Systolic heart failure is the most common complication in the acute phase of Takotsubo syndrome, occurring in 12-45% of cases. 4, 6, 7, 17, 80, 92 Independent predictors of acute heart failure are advanced age, low LVEF at presentation, higher admission and peak troponin levels, and a physical stressor preceding the onset of symptoms. Mechanical ventilation, inotropic support, and intra-aortic balloon pumping have been required in a substantial number of cases (28%, 38%, and 17%, respectively). 93 In some patients, pulmonary oedema due to acute LV dysfunction is exacerbated by mitral regurgitation, LVOTO or both.
Left ventricular outflow tract obstruction (LVOTO)
During the acute phase, a dynamic intraventricular pressure gradient due to mitral valve systolic anterior motion may develop as a consequence of myocardial stunning of the apical segments and hypercontraction of the basal LV myocardium. Significant LVOTO with gradients of 20-140 mm Hg have been observed in 10-25% of patients, often accompanied by mitral regurgitation. 7, 80, 94 A midventricular or LVOTO gradient >25 mm Hg is considered haemodynamically significant, and a gradient ≥40 mm Hg is a high-risk factor. Abnormal Q waves, hypotension, and cardiogenic shock are more frequent in these patients. Use of inotropic drugs or nitrates may exacerbate LVOTO, whereas beta-blockade with propranolol decreases the gradient. 95, 96 Normally LVOTO resolves spontaneously over a few days.
Mitral regurgitation
Acute mitral regurgitation is another potentially serious complication, occurring in 14-25% of patients. 97, 98 LVEF is lower and pulmonary artery pressure is higher in patients with significant regurgitation, who present more often with acute heart failure or cardiogenic shock. Two independent mechanisms may cause acute mitral regurgitation: systolic anterior motion of the mitral valve in association with dynamic LVOTO and apical tethering of the subvalvular mitral valve apparatus. 98, 99 In most cases, the mitral regurgitation decreases as LV function returns to normal, although recovery may be slower than in patients without acute mitral regurgitation.
Cardiogenic shock
Cardiogenic shock, primarily due to acute LV dysfunction, occurs in 4-20% of patients with Takotsubo syndrome and may be exacerbated by RV involvement, LVOTO, or acute mitral regurgitation. Echocardiography may identify the mechanism and help guide therapy. The mortality of cardiogenic shock in Takotsubo syndrome is high (17-30%).
6, 80, 91, 92, 100
Arrhythmias
Arrhythmias are common in patients with Takotsubo syndrome. New atrial fibrillation has been reported in 5-15% of cases. 6, 92, 101, 102 This arrhythmia further reduces cardiac output and is often associated with the onset of heart failure. Ventricular arrhythmias occur in 4-9% of patients during the acute phase of the syndrome, 6, 92, 101-103 causing cardiac arrest in 4-6% of cases. In rare instances, ventricular arrhythmias have been documented weeks after the first manifestation of Takotsubo syndrome, when LV function had already normalized. Bradycardia due to atrioventricular block and asystole has also been described.
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Thrombus formation
Thrombus in the akinetic ventricular apex is observed in 2-8% of Takotsubo syndrome patients, occasionally resulting in stroke or arterial embolism. 92, 104, 105 Best visualized by CMR imaging in early postcontrast acquisition sequences, most thrombi develop 2-5 days after symptom onset, when LV function is still depressed. However, new thrombus formation and subsequent embolism have also been described 14 days after symptom onset, when LV systolic function had already returned to normal. LV thrombi may resolve with 2 weeks of therapeutic anticoagulation, but a longer course (usually 3 months) should be considered, and follow-up imaging is advisable to confirm recovery of apical contractile function. 106 Prophylactic anticoagulation in higher-risk Takotsubo syndrome cases has an as-yet undetermined role but may be considered (see Management Algorithm for higher-risk individuals).
Pericardial effusion
Acute pericarditis with recurrent chest pain, reappearance of ST-segment elevation, and a small amount of pericardial effusion has been observed in some patients during the recovery phase of Takotsubo syndrome. 107 CMR imaging early after admission has detected small pericardial effusions in ~43% of patients. Pericardial tamponade requiring pericardiocentesis is rare (0.05%).
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Ventricular wall rupture
Serious mechanical complications, including ventricular free wall rupture or interventricular septal perforation are rare (<1%); they occur 2-8 days after symptom onset, often with persistent ST elevation. 92, 109, 110 A high outflow tract gradient may favour rupture of the LV free wall. One case of RV rupture has been described. Interventricular septum perforation and acquired ventricular septal defect can complicate Takotsubo syndrome and may be successfully treated by surgery.
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Right ventricular involvement
Patients with biventricular involvement generally have a more severe clinical course. RV involvement assessed by echocardiography or magnetic resonance imaging has been reported (18-34% cases) and is associated with older age, lower LVEF, a higher frequency of heart failure, pleural effusion and a longer hospital stay. 92, 113 Rarely, a pressure gradient or an apical thrombus may be present in the right ventricle.
Mortality during the acute episode
In large studies and registries of Takotsubo syndrome patients, the in-hospital mortality rate is 2-5%; death is mainly caused by refractory cardiogenic shock or ventricular fibrillation. 80, 91, 92 In a metaanalysis of 2120 patients in 37 studies, the in-hospital mortality rate was 4.5%, 114 consistent with the 4.2% in-hospital mortality reported in the large NIS-USA Takotsubo syndrome cohorts. 
Long-term prognosis
There are conflicting reports and data regarding the long-term survival of patients after their initial episode of Takotsubo syndrome. In two studies, 4-year survival was not different from that of an ageand gender-matched population. 115, 116 However, in two other studies, survival at 3 years was significantly lower than that of a matched general population. 100, 117 In the prospective SWEDEHEART registry, 3-year mortality was similar to that of NSTEMI and STEMI controls, and 
Clinical management (see Diagnostic and Management Algorithms)
General considerations
There are no randomised clinical trials to support specific treatment recommendations in Takotsubo syndrome. A key feature of Takotsubo syndrome is recovery of normal cardiac function. The major objective of in-hospital treatment should be supportive care to sustain life and to minimise complications during recovery. In mild cases, no treatment or a short course of limited medical therapy may be sufficient. In severe cases complicated by progressive circulatory failure and cardiogenic shock, early mechanical support early should be considered as a 'bridge-to-recovery'.
Diagnostic and management algorithms have been generated to help guide clinical decisionmaking. Risk stratification is essential to select treatment for patients at greatest risk of complications and to minimise interventions in patients at low risk where evidence for treatment is lacking. Given the lack of evidence from randomised controlled trials, the diagnostic and management algorithms are based on expert consensus and require validation in prospective trials. One overriding consideration in a condition with a high rate of functional recovery is to respect the fundamental ethical principle in medicine: primum non nocere (first, do no harm).
Once the diagnosis is confirmed, it may be helpful to enquire about previous episodes of unexplained chest pain, and in particular hospital admissions for chest pain or MI. In some cases, the index presentation is clearly a recurrence of Takotsubo syndrome (see Prevention of recurrence section).
In diagnosing borderline cases, it may be helpful to review the history to identify stressful triggers or co-existing medical conditions that may lead to sudden rises in sympathetic neural activity and systemic catecholamine levels. If the diagnosis is still uncertain, cardiac mIBG may be considered to evaluate regional myocardial sympathetic innervation and tone. It may be necessary to reserve judgement until follow-up imaging at 3 months confirms recovery of any RWMA present during the acute phase and clarifies the presence or absence of permanent LGE by CMR.
Risk stratification
Takotsubo syndrome has been generally regarded a relatively benign disease with rapid recovery of LV function. However, a variety of complications occurs in ~52% of the patients (Table 3) . 80, 91, 92 After diagnosis, we recommend that patients with Takotsubo However, given the absence of randomised trial evidence, it does not replace clinical judgement.
Validation of risk stratification algorithm requires a prospective study, and therefore this proposal is currently based on expect opinion (level of evidence C).
Management of lower-risk cases of Takotsubo syndrome
In milder cases with an LVEF >45% and no complications, the patient may be considered for early discharge from hospital. Before discharge, however, a review of medication is recommended, as many patients will have been started on treatment for ACS before coronary angiography, and indications for antiplatelet agents and statins should be reviewed. If LVEF is 35-45% but the patient is otherwise at lower risk, heart failure medications including beta-blockers should be considered. In preclinical studies, metoprolol and carvedilol have been beneficial, and these beta-blockers could be used unless contraindicated (e.g., reversible airways disease). 120, 121 Some experts suggest that vasoactive drugs, including angiotensin-converting enzyme (ACE) inhibitors, should be avoided in patients with normal cardiac output, as some Takotsubo syndrome patients may have altered peripheral sympathetic nerve activity associated with low peripheral vascular resistance.
Takotsubo syndrome patients in the lower-risk category should be followed for 3-6 months after discharge. The follow-up should include review of medications and cardiac imaging to confirm recovery of the RWMA.
Management of higher-risk cases of Takotsubo syndrome
General considerations
Takotsubo syndrome cases meeting criteria for higher risk should be monitored in a level 2 environment (e.g. coronary care unit or high-dependency unit) with continuous ECG monitoring and access to resuscitation equipment for at least 72 hours after presentation, when risk of life-threatening complications is greatest. 92 The opinion of a specialist (e.g. cardiologist with a special interest in heart failure) should be sought where available. Patients with decreased cardiac output should be considered for regular echocardiographic monitoring. Cessation of drugs with sympathomimetic properties is advised (e.g., catecholamines, β2-agonists). Beta-blockers may be considered in haemodynamically stable patients and in patients with atrial or ventricular tachyarrhythmias. In patients with haemodynamically significant LVOTO (LVOTO >40 mm Hg and systolic blood pressure <110 mm Hg), treatment with a beta-blocker or selective alpha-1 agonist (e.g. 
Mechanical support
Intra-aortic balloon counterpulsation (IABP) has been used to treat cardiogenic shock due to Takotsubo syndrome. However, in light of recent neutral data from the IABP-SHOCK II trial and the fact that IABP may worsen dynamic LVOTO, the consensus viewpoint is to avoid use of IABP in Takotsubo syndrome patients. If a patient with primary Takotsubo syndrome is deteriorating and has a low cardiac output, cardiogenic shock, and progressive multiorgan failure, specialist advice about ECMO or LVAD as a bridge-to-recovery is recommended, as there is an excellent chance that ventricular function will recover fully. [125] [126] [127] [128] In cases of secondary Takotsubo syndrome complicated by cardiogenic shock, the nature, severity, and prognosis of the underlying medical condition will determine whether mechanical cardiac support is warranted during the acute phase.
Levosimendan
The role of levosimendan is more controversial, with mixed expert opinion based on preclinical and limited clinical experience. 120, [129] [130] [131] [132] [133] In the absence of access to emergency mechanical support, levosimendan may be preferable to other inotropes such as dobutamine and epinephrine in patients who have advancing cardiogenic shock and multiorgan failure. Prospective randomised studies are required to assess the safety and efficacy of levosimendan in patients with Takotsubo syndrome and acute heart failure.
Access to all these advanced care options may vary and depend upon local expertise.
Preventing thromboembolism
Takotsubo syndrome may be associated with blood hypercoagulability reflecting the vasoconstrictor, platelet activation, or prothrombotic effects of high catecholamine levels. 134 Thromboembolism is a complication in ~4% of Takotsubo syndrome patients. Many patients with Takotsubo syndrome will initially receive antithrombotic treatment for suspected STEMI including dual antiplatelet therapy (aspirin and P2Y 12 receptor antagonists) and unfractionated or low-molecular-weight heparin. Once MI is excluded, consensus supports withdrawal of P2Y 12 receptor antagonists (clopidogrel, prasugrel, ticagrelor).
Oral anticoagulation is recommended if intraventricular thrombus is detected in a patient with
Takotsubo syndrome in the absence of high bleeding risk. Apical thrombus resolution and LV function recovery should be documented before anticoagulation is withdrawn. The role of prophylactic anticoagulation remains to be determined. Therapeutic low-molecular-weight heparin should be considered in cases with extensive segmental akinesia or atrial fibrillation.
Follow-up after hospital discharge
Regardless of the severity of their acute episode, all patients should be offered a follow-up assessment at 3-6 months. It should include repeat cardiac imaging to confirm the resolution of the acute RWMA and ECG changes observed and to exclude MI by CMR with LGE if not performed during the acute admission and in borderline cases. A review of medication will ensure that any drug therapy for ACS has been stopped. If LV function has recovered, weaning from the ACE inhibitor and beta-blocker can be considered in the absence of other indications.
There is currently no evidence to guide the long-term management of patients after an episode of Takotsubo syndrome. Some patients have persistent cardiac symptoms after LVEF and RWMA have normalised, 135 including chest pain, palpitations, and exertional breathlessness. Further investigations to define the cause and treatment are advised, as ongoing cardiac abnormalities (e.g., microvascular perfusion abnormalities, atrial arrhythmias) may arise months or years after the acute episode.
Given the high risk of complications during the acute phase, patients with recurrent episodes of Takotsubo syndrome may warrant long-term follow-up to identify strategies to minimise or prevent further recurrence (see below).
Preventing recurrence
Prevention of recurrent Takotsubo syndrome has not been demonstrated in any study. Intuitively, beta-blockers may provide some protection against future catecholamine surges. However, recurrences have been reported in patients taking beta-blockers, and one meta-analysis found no impact of beta-blockers on the risk of recurrence, although recurrence was infrequent in both arms. 136, 137 Nevertheless, there may be a role for beta-blockers in selected patients, such as those with evidence of persistently elevated sympathetic tone, ongoing cardiac symptoms (not clinically recovered), and persistent anxiety and those with recurrent Takotsubo syndrome.
There is evidence that anxiety states are more frequent in some patients with Takotsubo syndrome. Given the high frequency of stressful triggers in cases of primary Takotsubo syndrome, the psychological response to stress is another potential therapeutic target. The benefit of psychological counselling and cognitive behavioural therapy remains to be determined, but they may have a role in selected cases of recurrence triggered by emotional stressors and in cases of confirmed anxiety disorder.
Late-presenting cases (Box 5)
Some patients have delayed access to medical care or request a retrospective assessment of 'troponinpositive chest pain episodes with normal coronary arteries' lacking a diagnosis. A careful review of the history and risk factor profile may alter the probability that the episode in question was an acute Takotsubo 
Conclusion and future directions
Takotsubo syndrome is a fascinating acute heart failure syndrome, now increasingly recognised by the medical community. Many facets of this condition are incompletely understood or characterised, and current knowledge to guide optimal clinical management is limited. However, the increasing incidence and the high frequency of complications during the acute phase underpin the need to improve care pathways for patients with Takotsubo syndrome.
To date, clinical reports are mostly based on relatively small cohorts and case series. Therefore, the recommendations of this Position Statement reflect the consensus of expert opinion (level of evidence C). Randomised controlled trials are needed to identify optimal diagnostic and management strategies for Takotsubo syndrome. The potential for national and international registries to collect larger numbers of patients prospectively should aid understanding of the epidemiology and natural history. Takotsubo syndrome networks may also provide the infrastructure for research studies and, in particular, given the lack of current evidence-based treatments, for assessing novel therapeutic strategies. Individual hospitals may see no more than ~5-30 cases per annum, and broader networks are required to collect larger numbers of patients. Several countries have started to coordinate data collection in regional or national registries, and one international registry, the InterTAK registry (NCT01947621), has been launched to gather 10-year follow-up data on a large cohort of prospectively enrolled patients with confirmed Takotsubo syndrome. This is the first Position Statement from the ESC Heart Failure Association for this acute heart failure syndrome. It will be updated when further advances in the understanding and management of Takotsubo syndrome are available and particularly when results from randomised controlled trials are available to provide a stronger evidence base for clinical decision-making. 
Abbreviations
5.
Significantly elevated serum natriuretic peptide (BNP or NT-proBNP) during the acute phase.
6. Positive but relatively small elevation in cardiac troponin measured with a conventional assay (i.e., disparity between the troponin level and the amount of dysfunctional myocardium present). ‡
7.
Recovery of ventricular systolic function on cardiac imaging at follow-up (3-6 months). § *Acute, reversible dysfunction of a single coronary territory has been reported. † Left bundle branch block may be permanent after Takotsubo syndrome, but should also alert clinicians to exclude other cardiomyopathies. T-wave changes and QTc prolongation may take many weeks to months to normalize after recovery of LV function. ‡ Troponin-negative cases have been reported, but are atypical. § Small apical infarcts have been reported. Bystander subendocardial infarcts have been reported, involving a small proportion of the acutely dysfunctional myocardium. These infarcts are insufficient to explain the acute RWMA observed.
Box 3 Summary of pathophysiological hypotheses
Vascular Acute multivessel coronary spasm.
Aborted myocardial infarction with spontaneous recanalization.
Acute increased ventricular afterload.
Myocardial
Acute LVOTO.
Direct catecholamine-mediated myocardial stunning.
Vascular and myocardial
Integrated cardiovascular physiology (a cardio-circulatory syndrome). 
Box 4 HFA Risk stratification in Takotsubo syndrome
